ECSP21004913A - Compuestos coagonistas de gip/glp1 - Google Patents

Compuestos coagonistas de gip/glp1

Info

Publication number
ECSP21004913A
ECSP21004913A ECSENADI20214913A ECDI202104913A ECSP21004913A EC SP21004913 A ECSP21004913 A EC SP21004913A EC SENADI20214913 A ECSENADI20214913 A EC SENADI20214913A EC DI202104913 A ECDI202104913 A EC DI202104913A EC SP21004913 A ECSP21004913 A EC SP21004913A
Authority
EC
Ecuador
Prior art keywords
compounds
gip
coagonists
glp1
relates
Prior art date
Application number
ECSENADI20214913A
Other languages
English (en)
Inventor
Over Cabrera
Thi Thanh Huyen Tran
James Lincoln Wallis
Hongchang Qu
Aktham Aburub
Tamer Coskun
Francis Stafford Willard
Amita Datta-Mannan
Mohamed Elsayed Hamed Elsayed
Robert Chadwick Cummins
Robert Andrew Brown
Milata Mary Abraham
Xianyin Lai
Phenil Jayantilal Patel
Jorge Alsina-Fernandez
Kyle Wynn Sloop
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP21004913A publication Critical patent/ECSP21004913A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a compuestosque tienen actividad sobre ambos receptores humanos del polipéptido insulinotrópico dependiente de glucosa (GIP) y del péptido-1 similar al glucagón (GLP-1). La presente invención también se refiere a los compuestos que tienen una acción de duración prolongada en cada uno de estos receptores. Además, la presente invención también se refiere a los compuestos que puede administrarse de manera oral. Los compuestos pueden ser útiles en el tratamiento de la diabetes mellitus tipo 2 (“DMT2”). Además, los compuestos pueden ser útiles en el tratamiento de la obesidad.
ECSENADI20214913A 2018-07-23 2021-01-22 Compuestos coagonistas de gip/glp1 ECSP21004913A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862702072P 2018-07-23 2018-07-23
US201862730563P 2018-09-13 2018-09-13
US201862740596P 2018-10-03 2018-10-03

Publications (1)

Publication Number Publication Date
ECSP21004913A true ECSP21004913A (es) 2021-02-26

Family

ID=67620523

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20214913A ECSP21004913A (es) 2018-07-23 2021-01-22 Compuestos coagonistas de gip/glp1

Country Status (23)

Country Link
US (2) US11084861B2 (es)
EP (1) EP3827015A1 (es)
JP (3) JP6920559B2 (es)
KR (3) KR20240051304A (es)
CN (1) CN112469731A (es)
AU (2) AU2019311000B2 (es)
BR (1) BR112020026671A2 (es)
CA (2) CA3107345A1 (es)
CL (1) CL2021000158A1 (es)
CO (1) CO2021000453A2 (es)
CR (1) CR20210040A (es)
DO (1) DOP2021000016A (es)
EC (1) ECSP21004913A (es)
IL (1) IL279827A (es)
JO (1) JOP20210016A1 (es)
MA (1) MA53382A (es)
MX (1) MX2021000793A (es)
MY (1) MY197569A (es)
PE (1) PE20211637A1 (es)
PH (1) PH12021550154A1 (es)
SG (1) SG11202100128UA (es)
TW (3) TW202332688A (es)
WO (1) WO2020023386A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212180A1 (en) 2013-12-18 2023-07-19 The Scripps Research Institute Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
KR20240051304A (ko) * 2018-07-23 2024-04-19 일라이 릴리 앤드 캄파니 Gip/glp1 공효능제 화합물
KR20210024081A (ko) * 2018-07-23 2021-03-04 일라이 릴리 앤드 캄파니 당뇨병을 위한 gip/glp1 공효능제의 사용 방법
JP2022545200A (ja) 2019-08-19 2022-10-26 イーライ リリー アンド カンパニー インクレチン類似体を作製する方法
AU2021229621B2 (en) 2020-03-06 2023-08-31 Sanofi Peptides as selective GIP receptor agonists
US20230127047A1 (en) 2020-03-31 2023-04-27 Antaros Medical Ab Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
CA3184723A1 (en) 2020-07-22 2022-01-27 Patrick J. KNERR Glp-1 and gip receptor co-agonists
IL299701A (en) 2020-07-22 2023-03-01 Novo Nordisk As GLP-1 and GIP receptor co-agonists suitable for oral administration
BR112023003668A2 (pt) 2020-10-17 2023-04-25 Sun Pharmaceutical Ind Ltd Agonistas duplos de glp-1/gip
AR124295A1 (es) * 2020-12-18 2023-03-15 Lilly Co Eli Agonistas duales del receptor de amilina y calcitonina y usos de los mismos
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
JP2024508745A (ja) 2021-02-17 2024-02-28 イーライ リリー アンド カンパニー Ｇｉｐ／ｇｌｐ１デュアルアゴニスト治療方法
AR125086A1 (es) * 2021-03-23 2023-06-07 Lilly Co Eli Composiciones que contienen análogos de incretina y usos de estas
WO2022235991A1 (en) 2021-05-07 2022-11-10 Eli Lilly And Company Erodible tablet
CN113332416B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备治疗非酒精性脂肪肝药物中的应用
JP2024516070A (ja) * 2021-05-28 2024-04-12 広東衆生睿創生物科技有限公司 ポリペプチドの調製およびその使用
WO2022253202A1 (zh) * 2021-06-01 2022-12-08 南京知和医药科技有限公司 一种glp-1r和gipr双重靶向激动作用的多肽衍生物及其制备方法和用途
CA3230915A1 (en) 2021-09-06 2023-03-09 Thomas Boehme New peptides as potent and selective gip receptor agonists
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN117402219A (zh) * 2022-07-13 2024-01-16 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
WO2024050289A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions for oral delivery
WO2024059674A1 (en) * 2022-09-15 2024-03-21 Eli Lilly And Company Gip and glp-1 dual agonist compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012138941A1 (en) * 2011-04-05 2012-10-11 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
CN104470948B (zh) * 2012-05-03 2018-06-15 西兰制药公司 Gip-glp-1双激动剂化合物及方法
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
CN105324125A (zh) * 2013-03-15 2016-02-10 印第安纳大学研究及科技有限公司 具有长效的前体药物
MY172578A (en) 2013-05-02 2019-12-03 Novo Nordisk As Oral dosing of glp-1 compounds
CA2929459C (en) * 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198604A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
WO2017112897A1 (en) * 2015-12-22 2017-06-29 Engineered Controls International, Llc Noise reducing filler valve
TWI767095B (zh) 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
KR20240051304A (ko) * 2018-07-23 2024-04-19 일라이 릴리 앤드 캄파니 Gip/glp1 공효능제 화합물

Also Published As

Publication number Publication date
US20200024322A1 (en) 2020-01-23
MX2021000793A (es) 2021-04-12
JP6920559B2 (ja) 2021-08-18
KR102351313B1 (ko) 2022-01-17
JP2021508731A (ja) 2021-03-11
CN112469731A (zh) 2021-03-09
MY197569A (en) 2023-06-25
JP2023171775A (ja) 2023-12-05
TW202019952A (zh) 2020-06-01
DOP2021000016A (es) 2021-03-15
CL2021000158A1 (es) 2021-07-30
US20220048967A1 (en) 2022-02-17
WO2020023386A1 (en) 2020-01-30
KR20240051304A (ko) 2024-04-19
MA53382A (fr) 2021-06-02
AU2019311000A1 (en) 2021-02-25
IL279827A (en) 2021-03-01
EP3827015A1 (en) 2021-06-02
CR20210040A (es) 2021-02-12
AU2023202709A1 (en) 2023-05-18
KR20210031533A (ko) 2021-03-19
KR20210016632A (ko) 2021-02-16
TW202140527A (zh) 2021-11-01
TWI810606B (zh) 2023-08-01
PH12021550154A1 (en) 2021-09-13
BR112020026671A2 (pt) 2021-04-06
JP2021183614A (ja) 2021-12-02
CA3107345A1 (en) 2020-01-30
TW202332688A (zh) 2023-08-16
TWI735917B (zh) 2021-08-11
JOP20210016A1 (ar) 2021-01-21
CO2021000453A2 (es) 2021-01-29
US11084861B2 (en) 2021-08-10
AU2019311000B2 (en) 2023-02-02
PE20211637A1 (es) 2021-08-24
SG11202100128UA (en) 2021-02-25
CA3178366A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
ECSP21004913A (es) Compuestos coagonistas de gip/glp1
DOP2021000273A (es) Agonistas del receptor del péptido-1 similar al glucagón
ECSP22008098A (es) Compuestos agonistas de gipr
PE20170954A1 (es) Compuestos co-agonistas de gip y glp-1
AR121093A1 (es) Compuestos coagonistas de gip / glp1
BR112021020071A2 (pt) Compostos agonistas duplos do receptor de glp-1 e gip e uso dos mesmos
CO2020012425A2 (es) Análogos novedosos de glp-1
JP2020533302A5 (es)
CL2017002293A1 (es) Tratamiento de pacientes con diabetes mellitus de tipo 2
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
DOP2022000122A (es) Analogos de incretina y sus usos
CO2022004572A2 (es) Tratamiento de la diabetes mellitus tipo 2
EA202092891A1 (ru) Соединения-коагонисты gip/glp1
BR112023024968A2 (pt) Tratamento da obesidade e distúrbios relacionados à obesidade
EA202192296A1 (ru) Терапевтическое применение дулаглутида
AR102978A1 (es) Formulación de relación fija de insulina glargina / lixisenatida